 |
PDBsum entry 1mts
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Serine proteinase
|
PDB id
|
|
|
|
1mts
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.21.4
- trypsin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Preferential cleavage: Arg-|-Xaa, Lys-|-Xaa.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
FEBS Lett
375:103-107
(1995)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin.
|
|
M.T.Stubbs,
R.Huber,
W.Bode.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Crystal structures of DX9065a and a related bisamidino-aryl inhibitor specific
for the blood-clotting factor Xa have been solved in complex with bovine
beta-trypsin to a resolution of 1.9 A. Each inhibitor exhibits an extended
conformation along the active site, in contrast to the compact folded structures
observed for thrombin specific inhibitors. Few direct contacts (predominantly in
the S1 pocket) are made between trypsin and the inhibitors. Transfer of the
inhibitors to the active site of factor Xa suggests a three-site interaction:
salt bridge formation at the base of the primary specificity pocket, extensive
hydrophobic surface burial and a weak electrostatic interaction between the
distal basic component of the inhibitor and an electronegative cavity of factor
Xa formed by three backbone carbonyl oxygens. Additivity of these three
interactions is the basis for the observed strong inhibition of factor Xa and
provides a framework for the design of novel factor Xa inhibitors. A propionic
acid group of the inhibitor would clash with the thrombin specific '60-insertion
loop', thus conferring selectivity against thrombin.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
D.R.Carrillo,
C.Parthier,
N.Jänckel,
J.Grandke,
M.Stelter,
S.Schilling,
M.Boehme,
P.Neumann,
R.Wolf,
H.U.Demuth,
M.T.Stubbs,
and
J.U.Rahfeld
(2010).
Kinetic and structural characterization of bacterial glutaminyl cyclases from Zymomonas mobilis and Myxococcus xanthus.
|
| |
Biol Chem,
391,
1419-1428.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Di Fenza,
A.Heine,
U.Koert,
and
G.Klebe
(2007).
Understanding Binding Selectivity toward Trypsin and Factor Xa: the Role of Aromatic Interactions.
|
| |
ChemMedChem,
2,
297-308.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Z.Zhu,
Z.Liang,
T.Zhang,
Z.Zhu,
W.Xu,
M.Teng,
and
L.Niu
(2005).
Crystal structures and amidolytic activities of two glycosylated snake venom serine proteinases.
|
| |
J Biol Chem,
280,
10524-10529.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.A.Kontogiorgis,
and
D.Hadjipavlou-Litina
(2004).
Current trends in quantitative structure activity relationships on FXa inhibitors: evaluation and comparative analysis.
|
| |
Med Res Rev,
24,
687-747.
|
 |
|
|
|
|
 |
D.Rauh,
S.Reyda,
G.Klebe,
and
M.T.Stubbs
(2002).
Trypsin mutants for structure-based drug design: expression, refolding and crystallisation.
|
| |
Biol Chem,
383,
1309-1314.
|
 |
|
|
|
|
 |
M.M.Mueller,
S.Sperl,
J.Stürzebecher,
W.Bode,
and
L.Moroder
(2002).
(R)-3-Amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode.
|
| |
Biol Chem,
383,
1185-1191.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.E.Robinson,
and
A.B.Robinson
(2001).
Prediction of protein deamidation rates from primary and three-dimensional structure.
|
| |
Proc Natl Acad Sci U S A,
98,
4367-4372.
|
 |
|
|
|
|
 |
S.Sperl,
A.Bergner,
J.Stürzebecher,
V.Magdolen,
W.Bode,
and
L.Moroder
(2000).
Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies.
|
| |
Biol Chem,
381,
321-329.
|
 |
|
|
|
|
 |
V.L.Nienaber,
D.Davidson,
R.Edalji,
V.L.Giranda,
V.Klinghofer,
J.Henkin,
P.Magdalinos,
R.Mantei,
S.Merrick,
J.M.Severin,
R.A.Smith,
K.Stewart,
K.Walter,
J.Wang,
M.Wendt,
M.Weitzberg,
X.Zhao,
and
T.Rockway
(2000).
Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite.
|
| |
Structure,
8,
553-563.
|
 |
|
|
|
|
 |
M.S.Rao,
and
A.J.Olson
(1999).
Modelling of factor Xa-inhibitor complexes: a computational flexible docking approach.
|
| |
Proteins,
34,
173-183.
|
 |
|
|
|
|
 |
M.Whitlow,
D.O.Arnaiz,
B.O.Buckman,
D.D.Davey,
B.Griedel,
W.J.Guilford,
S.K.Koovakkat,
A.Liang,
R.Mohan,
G.B.Phillips,
M.Seto,
K.J.Shaw,
W.Xu,
Z.Zhao,
D.R.Light,
and
M.M.Morrissey
(1999).
Crystallographic analysis of potent and selective factor Xa inhibitors complexed to bovine trypsin.
|
| |
Acta Crystallogr D Biol Crystallogr,
55,
1395-1404.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.Zhou,
and
M.E.Johnson
(1999).
Comparative molecular modeling analysis of-5-amidinoindole and benzamidine binding to thrombin and trypsin: specific H-bond formation contributes to high 5-amidinoindole potency and selectivity for thrombin and factor Xa.
|
| |
J Mol Recognit,
12,
235-241.
|
 |
|
|
|
|
 |
F.Fraternali,
Q.T.Do,
B.T.Doan,
R.A.Atkinson,
P.Palmas,
V.Sklenar,
P.Safar,
P.Wildgoose,
P.Strop,
and
V.Saudek
(1998).
Mapping the active site of factor Xa by selective inhibitors: an NMR and MD study.
|
| |
Proteins,
30,
264-274.
|
 |
|
|
|
|
 |
K.P.Hopfner,
H.Brandstetter,
A.Karcher,
E.Kopetzki,
R.Huber,
R.A.Engh,
and
W.Bode
(1997).
Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants.
|
| |
EMBO J,
16,
6626-6635.
|
 |
|
|
|
|
 |
M.Renatus,
W.Bode,
R.Huber,
J.Stürzebecher,
D.Prasa,
S.Fischer,
U.Kohnert,
and
M.T.Stubbs
(1997).
Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors.
|
| |
J Biol Chem,
272,
21713-21719.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.T.Stubbs,
R.Morenweiser,
J.Stürzebecher,
M.Bauer,
W.Bode,
R.Huber,
G.P.Piechottka,
G.Matschiner,
C.P.Sommerhoff,
H.Fritz,
and
E.A.Auerswald
(1997).
The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin. Implications for the structure of human mast cell tryptase and its inhibition.
|
| |
J Biol Chem,
272,
19931-19937.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.van de Locht,
M.T.Stubbs,
W.Bode,
T.Friedrich,
C.Bollschweiler,
W.Höffken,
and
R.Huber
(1996).
The ornithodorin-thrombin crystal structure, a key to the TAP enigma?
|
| |
EMBO J,
15,
6011-6017.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.A.Huntington,
S.T.Olson,
B.Fan,
and
P.G.Gettins
(1996).
Mechanism of heparin activation of antithrombin. Evidence for reactive center loop preinsertion with expulsion upon heparin binding.
|
| |
Biochemistry,
35,
8495-8503.
|
 |
|
|
|
|
 |
R.A.Engh,
H.Brandstetter,
G.Sucher,
A.Eichinger,
U.Baumann,
W.Bode,
R.Huber,
T.Poll,
R.Rudolph,
and
W.von der Saal
(1996).
Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design.
|
| |
Structure,
4,
1353-1362.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |